| Bioactivity | Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer[1]. |
| In Vivo | Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 Nu/Nu 小鼠的 U87MGde2-7 多形性胶质母细胞瘤 (GBM) 模型和 A431 鳞状荷瘤模型中显著抑制肿瘤生长[1]。Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 NSG 小鼠的 EGFRvIII 阳性 GBM-SN0199-PDX 模型中抑制肿瘤生长和 pEGFR 水平[1]。Depatuxizumab (2-40 mg/kg， i.p.， 每周三次， 持续2周) 在 SCID Beige 小鼠的 SCC15 荷瘤模型中以剂量依赖方式抑制肿瘤生长[1]。 Animal Model: |
| Name | Depatuxizumab |
| CAS | 1471999-69-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. |